Abbonarsi

Focal point technology: Controlling treatment depth and pattern of skin injury by a novel highly focused laser - 18/12/24

Doi : 10.1016/j.jaad.2024.09.004 
Dieter Manstein, MD, PhD a, b, Henry H. Chan, MD, PhD b, c, d, Jayant Bhawalkar, PhD e, , Irina Erenburg, PhD b, e, Hyemin Pomerantz, MD e, f, Jhony Escobar, BS b, Zeina Tannous, MD d, e, g, Jane Yoo, MD, MPP e, h, Thanh-Nga Tran, MD, PhD d, e, Raj Katkam, MS e, R. Rox Anderson, MD b, d
a Department of Dermatology, Cutaneous Biology Research Center, Harvard Medical School, Charlestown, Massachusetts 
b Blossom Innovations, Waltham, Massachusetts 
c Division of Dermatology, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China 
d Department of Dermatology, Wellman Laboratories of Photomedicine, Harvard Medical School, Boston, Massachusetts 
e AVAVA, Inc, Waltham, Massachusetts 
f VivaSkin Dermatology and Aesthetics, Wellesley, Massachusetts 
g Department of Dermatology, Lebanese American University School of Medicine, Beirut, Lebanon 
h Clinical Research Center of New York, New York, New York 

Correspondence to: Jayant Bhawalkar, PhD, AVAVA Inc, 275 2nd Avenue, 3rd Floor, Waltham, MA 02451.AVAVA Inc275 2nd Avenue3rd FloorWalthamMA02451

Abstract

Background

Selective photothermolysis has limitations in efficacy and safety for dermal targets. We describe a novel concept using scanned focused laser microbeams for precise control of dermal depth and pattern of injury, using a 1550 nm laser that generates an array of conical thermal zones while minimizing injury to the epidermis.

Objective

To characterize the conical thermal zones in vivo and determine safe starting parameters to transition to a second phase to explore potential clinical indications.

Methods

A focused toroidal (ring) laser beam was delivered through a cold sapphire window, sparing epidermal injury in a central zone. Pulse energy, lesion depth, density, and energy delivery were titrated in ex vivo human skin and subsequently on the backs of 21 human subjects.

Results

Histology showed microscale patterns of thermal injury, which varied predictably with laser parameters. Time-course healing through histology and skin surface imaging demonstrated the ability of the device to deliver high energies without sequelae.

Limitations

Clinical data are currently being collected to further explore the safety and efficacy of the device.

Conclusion

The 1550 nm laser with focal point technology enables precise control of lesion depth while simultaneously sparing a large portion of the epidermis, lowering the risk of adverse effects.

Il testo completo di questo articolo è disponibile in PDF.

Key words : 1550 nm, focal point technology, fractional, laser, microbeam, nonablative, photothermolysis, treatment

Abbreviations used : CTZ, FPT, FST, MENDS, NA, PIH


Mappa


 Funding sources: Supported by AVAVA Inc.; Dr Anderson was supported in part as the Lancer Endowed Chair in Dermatology at Massachusetts General Hospital.
 IRB approval status: The study was reviewed and approved by Salus IRB; Protocol #: AV-19-003. Additional clinical imaging from AV-22-001, AV-22-002.


© 2024  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 92 - N° 1

P. 78-84 - gennaio 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
  • Brett G.M. Hughes, Alexander Guminski, Samantha Bowyer, Michael R. Migden, Chrysalyne D. Schmults, Nikhil I. Khushalani, Anne Lynn S. Chang, Jean-Jacques Grob, Karl D. Lewis, George Ansstas, Fiona Day, Rahul Ladwa, Brian N. Stein, Eva Muñoz Couselo, Friedegund Meier, Axel Hauschild, Dirk Schadendorf, Nicole Basset-Seguin, Badri Modi, Sophie Dalac-Rat, Lara A. Dunn, Lukas Flatz, Laurent Mortier, Sarah Guégan, Lucie M. Heinzerling, Janice M. Mehnert, Sabiha Trabelsi, Ainara Soria-Rivas, Alexander J. Stratigos, Claas Ulrich, Deborah J. Wong, Marie Beylot-Barry, Paolo Bossi, Cristina Bugés Sánchez, Sunandana Chandra, Caroline Robert, Jeffery S. Russell, Ann W. Silk, Jocelyn Booth, Suk-Young Yoo, Frank Seebach, Israel Lowy, Matthew G. Fury, Danny Rischin
| Articolo seguente Articolo seguente
  • JAAD Game Changers: Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study
  • Adam Friedman

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.